Using iCAGES to guide cancer treatment for better outcomes
Official title: Multicentre Perspective Non-interventional Study of Survival Benefits of iCAGES-guided Therapy in Contrast to Standard Therapy or IHC-guided Therapy for Advanced Cancers
Run by Second Affiliated Hospital of Guangzhou Medical University · NCT03192501 · Data updated 2026-11-12
This study is testing if a new tool called iCAGES can help doctors choose better treatments for people with advanced cancers, like lung cancer, to see if it improves their survival and quality of life compared to standard care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Second Affiliated Hospital of Guangzhou Medical University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | July 1, 2017 |
| Main results expected | July 1, 2030 |
| Study ends | July 1, 2039 |
| Registry record updated | June 25, 2024 |
| Trial ID | NCT03192501 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with recurrent or metastatic lung cancer or other advanced cancers who can provide informed consent.
✕Probably not a fit
Patients over 70 years old, those with a history of malignant tumors, pregnant or lactating women, and individuals with serious concomitant diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the effectiveness of the iCAGES (integrated CAncer GEnome Score) tool in guiding treatment for advanced cancers compared to standard care or IHC-guided therapy. It aims to determine if iCAGES can improve progression-free survival, overall survival, and quality of life for patients with lung cancer and other advanced cancers. The study leverages high-throughput sequencing data to identify gene mutations and recommend targeted therapies based on individual genomic profiles. Patients will receive treatment options that are tailored to their specific genetic mutations, potentially enhancing treatment efficacy.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective cancer treatments, improving survival rates and quality of life for patients.
How similar studies have gone: Other studies utilizing precision medicine approaches have shown promise, suggesting that this method could be a meaningful advancement in cancer treatment.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathological and clinical diagnosis of recurrence / metastatic lung cancer or other advanced cancers. * There are PACS images available at the Second Affiliated Hospital of Guangzhou Medical University and the collaborated Hospitals. * The patient is informed consent and signed a written consent. Exclusion Criteria: * Age \> 70 or \<18 years old. * Previous history of malignant tumors. * Pregnant or lactating female patients. * Any serious concomitant disease that is expected to have an adverse effect on prognosis, including the heart disease that treatment is required, unsatisfactory controlled diabetes and psychiatric disorders.
Where it's running
-
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Principal investigator: Zhenfeng Zhang, MD,PhD — Second Affiliated Hospital of Guangzhou Medical University
- Study coordinator: Zhenfeng Zhang, MD,PhD
- Email: zhangzhf@gzhmu.edu.cn
- Phone: +86-020-34153532
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.